Demonstrating the value of medicines: evolution of value equation and stakeholder perception of uncertainties [0.03%]
展示药物价值的演变：价值等式的演变以及利益相关者对不确定性的看法
Siva Narayanan
Siva Narayanan
It is important to evaluate how the value of medicine is assessed, as it may have important implications for health technology and reimbursement assessments. The value equation could comprise 'incremental benefit/outcome' (relative results ...
Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles [0.03%]
儿童鼻内接种流感减毒活疫苗策略的直接和间接影响的成本效益分析：国家概况分析
Edward Gibson,Najida Begum,Federico Martinón-Torres et al.
Edward Gibson et al.
Background: Influenza poses a significant burden on healthcare systems and society, with under-recognition in the paediatric population. Existing vaccination policies (largely) target the elderly and other risk groups whe...
Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole [0.03%]
关于玻璃体黄斑牵引和黄斑孔治疗的奥曲肽疗效成本分析研究
Craig Bennison,Stephanie Stephens,Benedicte Lescrauwaet et al.
Craig Bennison et al.
Background: If left untreated, vitreomacular traction (VMT) will infrequently improve through spontaneous resolution of vitreomacular adhesion (VMA), and patients remain at risk of further deterioration in vision. The mai...
Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations [0.03%]
精神分裂症疾病的验证：美国和欧洲人口聚类分析的比较
Katia Thokagevistk,Aurélie Millier,Leslie Lenert et al.
Katia Thokagevistk et al.
Background: There is controversy as to whether use of statistical clustering methods to identify common disease patterns in schizophrenia identifies patterns generalizable across countries. ...
Feasibility and attractiveness of indication value-based pricing in key EU countries [0.03%]
基于价值的定价在欧盟主要国家的可行性和吸引力分析
Mathias Flume,Marc Bardou,Stefano Capri et al.
Mathias Flume et al.
Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country ...
Health economic value of an innovation: delimiting the scope and framework of future market entry agreements [0.03%]
创新的卫生经济学价值：界定未来市场准入协议的范围和框架
Robert Launois,Lucia Fiestas Navarrete,Olivier Ethgen et al.
Robert Launois et al.
Background and objectives: The objective of our paper is to offer a new, payer-friendly taxonomy of market entry agreements (MEAs) that aims to twin contracts with their methodological designs in an effort to clarify the ...
Anne-Lise Vataire,Laurent Cetinsoy,Samuel Aballéa et al.
Anne-Lise Vataire et al.
Background and objective: The value appreciation of new drugs across countries today features a disruption that is making the historical data that are used for forecasting pharmaceutical expenditure poorly reliable. Forec...
Is the gap between micro- and macroeconomic assessments in health care well understood? The case of vaccination and potential remedies [0.03%]
微观和宏观医疗评估之间的差距真的理解清楚了吗？以疫苗为例及其潜在的解决办法
Nikolaos Kotsopoulos,Mark P Connolly
Nikolaos Kotsopoulos
Vaccination is an established intervention that reduces the burden and prevents the spread of infectious diseases. Investing in vaccination is known to offer a wide range of economic and intangible benefits that can potentiate gains for the...
Mattias Haglund,Eric Miller
Mattias Haglund
Joshua P Cohen,Abigail Felix
Joshua P Cohen
Background: Some orphan drugs can cost hundreds of thousands of dollars annually per patient. As a result, payer sensitivity to the cost of orphan drugs is rising, particularly in light of increased numbers of new launche...